Related Experiment Videos
[Influence of interferon-alpha therapy on the count and function of T lymphocytes in children with chronic hepatitis
T Woźniakowska-Gesicka1, M Wiśniewska-Ligier, J Kupś
1III Klinika Pediatrii Instytutu Centrum Zdrowia Matki Polki w Łodzi.
Insights
Interferon-alpha therapy for children with chronic hepatitis C significantly boosted T lymphocyte subsets, enhancing immune response. This treatment increased CD4 lymphocytes and the CD4/CD8 ratio, aiding viral RNA elimination.
Area of Science:
- Immunology
- Hepatology
- Pediatrics
Context:
- Chronic hepatitis C affects children, impacting their immune system.
- T lymphocytes play a crucial role in managing viral infections like hepatitis C.
- Understanding immune responses in pediatric hepatitis C is vital for effective treatment.
Purpose:
- To evaluate the number and function of T lymphocytes in children with chronic hepatitis C.
- To assess the immunological effects of interferon-alpha (INF-alpha) therapy in pediatric patients.
- To correlate changes in T lymphocyte subsets with hepatitis C virus (HCV) RNA elimination.
Summary:
- The study involved 60 children with chronic hepatitis C, with 30 receiving 6 months of INF-alpha therapy, and 40 healthy children as controls.
- Flow cytometry was used to examine T lymphocyte subsets (CD3, CD4, CD8) and activation markers (CD3/HLADR, CD3/CD25) before and after treatment.
- INF-alpha therapy led to a significant increase in CD4 lymphocytes, a decrease in CD8 lymphocytes, an elevated CD4/CD8 ratio, and increased expression of activation markers.
Impact:
- Interferon-alpha therapy stimulates an immunological response in children with chronic hepatitis C.
- Increased CD4 lymphocytes and CD4/CD8 ratio correlate with successful HCV RNA elimination.
- Findings suggest INF-alpha can modulate T lymphocyte function, potentially improving outcomes in pediatric hepatitis C.
Abstract:
This study aims to assess number and function of T lymphocytes in children with chronic hepatitis persistent C. The study included 60 children with chronic hepatitis C. Among this group 30 were treated with interferon-alpha (INF-alpha) during 6 months. Forty healthy children were included in the study as the control group. We examined subsets of blood lymphocytes T (CD3, CD4, CD8) and lymphocytes with expression of CD3/HLADR, CD3/CD25 antigens using monoclonal antibodies IMK plus and flow cytometry, at the beginning and after 6 months. After INF-alpha therapy a significant increase in subset of CD4 lymphocytes, significant decrease in CD8, increase in CD4/CD8 ratio and increase in lymphocytes with expression CD3/HLADR, CD3/CD25 receptors were observed. Differences in CD8 lymphocytes and CD4/CD8 ratio in the treated children were statistical higher in children with elimination HCV RNA. Applying INF-alpha in children with chronic hepatitis C stimulated immunological response by increasing subsets of CD4 lymphocytes, CD4/CD8 ratio and stimulated lymphocytes.